Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection
- PMID: 17616021
- PMCID: PMC2687613
- DOI: 10.3904/kjim.2007.22.2.73
Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection
Abstract
Background: Spontaneous delayed clearance of hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection is a rare event. The aim of this study was to investigate the incidence of delayed clearance of serum HBsAg in chronic HBV infection and to determine the characteristics and clinical outcomes of HBsAg delayed clearance in Korean patients.
Methods: From April 1981 to June 2003, 4,061 patients who were positive for HBsAg were evaluated retrospectively. The following assessments were undertaken in 47 patients who had spontaneous delayed clearance: liver biochemistry, viral markers, alpha-fetoprotein levels, and radiographic examinations including ultrasonography every three to six months for 6-264 months (median 87.9 months).
Results: Twenty-four of 47 patients were asymptomatic carriers. The others included seven patients with chronic hepatitis, seven with liver cirrhosis and nine with hepatocellular carcinoma. The estimated annual incidence of HBsAg seroclearance was 0.4%. The time span from positive HBsAg to HBsAg seroclearance in the AHC, CH, LC, and HCC was 62.9, 141, 63, and 95.3 months during follow up. Twenty-four of 24 AHC remained normal, 5 of 7 CH remained as CH and 2 patients remained normal, 1 of 7 with LC developed HCC and 6 of the LC remained as LC, and 4 of 9 HCC patients died.
Conclusion: The clinical course following delayed clearance of HBsAg had diverse outcomes from AHC to HCC. Therefore, these patients require close follow up for the possible development of hepatocellular carcinoma following HBsAg clearance.
Similar articles
-
Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.Am J Med. 2006 Jan;119(1):71.e9-16. doi: 10.1016/j.amjmed.2005.02.033. Am J Med. 2006. PMID: 16431195
-
Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.World J Gastroenterol. 2016 Nov 28;22(44):9836-9843. doi: 10.3748/wjg.v22.i44.9836. World J Gastroenterol. 2016. PMID: 27956808 Free PMC article.
-
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.Gastroenterology. 2002 Oct;123(4):1084-9. doi: 10.1053/gast.2002.36026. Gastroenterology. 2002. PMID: 12360470
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
Hepatitis B surface antigen seroclearance during chronic HBV infection.Antivir Ther. 2010;15(2):133-43. doi: 10.3851/IMP1497. Antivir Ther. 2010. PMID: 20386068 Review.
Cited by
-
Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).J Clin Med. 2022 Feb 21;11(4):1126. doi: 10.3390/jcm11041126. J Clin Med. 2022. PMID: 35207397 Free PMC article. Review.
-
Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.Lancet Gastroenterol Hepatol. 2019 Mar;4(3):227-238. doi: 10.1016/S2468-1253(18)30308-X. Epub 2019 Jan 22. Lancet Gastroenterol Hepatol. 2019. PMID: 30679109 Free PMC article.
-
KASL clinical practice guidelines: management of chronic hepatitis B.Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044762 Free PMC article. Review. No abstract available.
-
Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome.Korean J Intern Med. 2012 Mar;27(1):47-52. doi: 10.3904/kjim.2012.27.1.47. Epub 2012 Feb 28. Korean J Intern Med. 2012. PMID: 22403499 Free PMC article.
-
Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.Am J Pathol. 2008 Sep;173(3):856-64. doi: 10.2353/ajpath.2008.080096. Epub 2008 Aug 7. Am J Pathol. 2008. PMID: 18688024 Free PMC article.
References
-
- Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–496. - PubMed
-
- Liaw YF. Natural history of chronic hepatitis B virus infection. In: Liaw YF, editor. Chronic hepatitis. Amsterdam: Elsevier; 1986. pp. 9–18.
-
- de Frachis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, Rumi MG, Donato MF, Ronchi G. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118:191–194. - PubMed
-
- Viola LA, Barrison IG, Coleman JC, Paradinas FJ, Fluker JL, Evans BA, Murray-Lyon IM. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Lancet. 1981;2:1156–1159. - PubMed
-
- Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145:1039–1047. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous